Apa tegese "Clear"?
Kewan ora nindakake mutasi. Ora bakal ngembangake penyakit kasebut lan ora bakal ngliwati.
Jaran Warmblood Foal Fragility Syndrom (WFFS)
The Warmblood Foal Fragility Syndrome (WFFS) DNA test is essential for horse breeders aiming to prevent this genetic disorder. WFFS is a hereditary condition affecting connective tissue, leading to fragile skin and early foal mortality. By using the WFFS DNA test, breeders can identify carriers and make informed breeding decisions to reduce the risk of affected foals. This test is quick, accurate, and widely recommended for Warmblood horses. Early detection through DNA testing helps maintain healthy bloodlines and improves overall herd quality. Ensure your Warmblood breeding program is safe by incorporating the WFFS DNA test today. Protect your foals and promote responsible breeding with this vital genetic screening.
Singkatan : WFFS
Analisa mutasi: PLOD1 c.2032G/A
Warisan : Autosomal resesif
Akronim
WFFS
Frekuensi sing diamati
Keruwetan klinis
Klasifikasi klinis
Gangguan Pangembangan
Mutasi sing dianalisis
PLOD1 c.2032G/A
p.(G678R)
p.(G678R)
Mode warisan
Autosomal resesif (Komplit)
Ringkesan tes:
Warmblood Foal Fragility Syndrome (WFFS) is a genetic disorder affecting horses, particularly warmblood breeds. It is caused by a mutation in the PLOD1 gene, leading to fragile skin and connective tissues in foals. A DNA test can identify carriers of the WFFS mutation, helping breeders avoid mating two carriers. Preventing carrier-to-carrier breeding reduces the risk of producing affected foals. This test is an important tool for responsible breeding and maintaining healthy horse populations.
Kasedhiya saka paket: Basic
Tes DNA iki kalebu wiwit saka paket kita Basic — lan uga bagéan saka ngemas Basic, Standard, Advanced, Complete.
Deleng Paket Tes DNA →Pilih paket sing paling cocog karo breeding utawa strategi kesehatan kewan sampeyan.
Introduction to Warmblood Foal Fragility Syndrome (WFFS)
Warmblood Foal Fragility Syndrome (WFFS) is a genetic disorder that affects foals, primarily within certain equine breeds. This condition results from a mutation in the gene responsible for collagen production, which is vital for the structural integrity of connective tissues. As a consequence, affected foals exhibit extreme fragility, making them susceptible to severe injuries and complications, particularly during the birthing process or shortly after birth.
Clinical Signs of WFFS
Foals diagnosed with WFFS typically display a range of clinical symptoms that can vary in severity. Common indicators include skin that is incredibly thin and fragile, which can lead to easy tearing and bruising. Additionally, these foals may experience joint laxity, making them prone to dislocations and other orthopedic issues. Other signs can include respiratory difficulties and a failure to thrive, which can significantly impact their overall development and survival rates.
Management and Care of Affected Foals
Managing a foal with WFFS requires a specialized approach to ensure their well-being. Due to their fragile condition, it is crucial to provide a calm and safe environment to minimize the risk of injury. Veterinary care is essential, including regular monitoring for any signs of complications. Supportive care, such as appropriate nutrition and gentle handling, can help improve the quality of life for these foals. In some cases, surgical interventions may be necessary to address specific injuries or complications that arise.
Genetic Counseling and Prevention
For breeders, understanding WFFS is vital for making informed breeding decisions. Genetic counseling can provide valuable insights into the risks associated with breeding horses that may carry the WFFS gene. Implementing genetic testing as part of a breeding program can help prevent the birth of affected foals, thereby reducing the incidence of this condition in future generations. Awareness and education about WFFS can also empower breeders to make responsible choices that prioritize the health and welfare of their horses.
Kesimpulan
Warmblood Foal Fragility Syndrome is a serious genetic condition that poses significant challenges for affected foals and their caretakers. Awareness of the symptoms, management strategies, and prevention methods is crucial in mitigating the impact of this syndrome. Through responsible breeding practices and genetic testing, the equine community can work towards reducing the prevalence of WFFS, ensuring healthier outcomes for future foals.
Jenis sing diakoni kanggo tes: Warmblood Foal Fragility Syndrom (WFFS)
- Thoroughbred
- Warmblood
🧬 Interpretation of genotypes WFFS
Genotip
Status
🟡 N/N
Non-carrier - Ora Risk
🟡 N/WFFS
Carrier - Ora Risk
❌ WFFS/WFFS
Kena pengaruh - Risk
FAQ: mangerteni interpretasi
Apa "Carrier" serius?
Ora. Kewan iki umume sehat nanging bisa nularake mutasi kasebut turunan.
Apa yen kewan "Kena pengaruh"?
Iki nggawa rong salinan mutasi. pratandha Clinical samesthine gumantung ing penyakit. Sampeyan kudu ora dikembangke.
Apa ana bedane antarane lanang / wadon?
Sawetara penyakit ana hubungane karo jinis, mula ekspresi kasebut beda-beda gumantung saka penyakit kasebut jinis kewan.
Prediksi Keturunan
N/N (non-pembawa)
N/WFFS (Pembawa)
WFFS/WFFS (kena pengaruh)
FAQ Tes DNA
Apa sing dideteksi tes DNA iki?
This DNA test detects the mutation associated with Warmblood Foal Fragility Syndrom (WFFS) in order to identify clear, carrier, or at-risk animals.
Napa nguji kewan breeding?
Tes DNA mbantu para peternak ngrancang kawin sing luwih aman lan nyuda risiko nularake mutasi menyang turunane.
Apa mode warisan saka tes iki?
Mode warisan sing dilapurake kanggo tes iki yaiku Autosomal Recessive.
Mutasi endi sing dianalisis ing tes iki?
This test analyses the mutation PLOD1 c.2032G/A.
Apa kewan operator kudu kena pengaruh?
Ora mesthi. Interpretasi gumantung saka pola warisan lan genotipe sing diasilake.
Referensi
Monthoux Chloé, de Brot Simone, Jackson Michelle, Bleul Ulrich, Walter Jasmin. Skin malformations in a neonatal foal tested homozygous positive for Warmblood Fragile Foal Syndrome. BMC Vet Res. 2015 Jan 31;11:12. doi: 10.1186/s12917-015-0318-8.